

General information about company	
Scrip code*	524404
NSE Symbol*	MARKSANS
MSEI Symbol*	NOTLISTED
ISIN*	INE750C01026
Name of company	MARKSANS PHARMA LIMITED
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2024
Date of end of financial year	31-03-2025
Date of board meeting when results were approved	19-05-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	08-05-2025
Description of presentation currency	INR
Level of rounding	Millions
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Pharmaceutical Formulation
Start date and time of board meeting	19-05-2025 18:30
End date and time of board meeting	19-05-2025 19:05
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	11-02-2025
Indicate Company website link for updated RPT policy of the Company	<a href="https://www.marksanspharma.com/codes-policies.html">https://www.marksanspharma.com/codes-policies.html</a>
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter	
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No The Company has not defaulted on loans and debt securities.

Financial Results - Ind-AS				
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period		01-01-2025	01-04-2024	
Date of end of reporting period		31-03-2025	31-03-2025	
Whether results are audited or unaudited		Audited	Audited	
Nature of report standalone or consolidated		Standalone	Standalone	
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>			
<b>1</b>	<b>Income</b>			
	Revenue from operations	2993.57	11743.74	
	Other income	78.17	698.34	
	<b>Total income</b>	<b>3071.74</b>	<b>12442.08</b>	
<b>2</b>	<b>Expenses</b>			
(a)	Cost of materials consumed	1450.6	5371.77	
(b)	Purchases of stock-in-trade	167.68	1020.61	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	23	6.98	
(d)	Employee benefit expense	288.18	1016.78	
(e)	Finance costs	3.11	11.74	
(f)	Depreciation, depletion and amortisation expense	81.77	294.52	
<b>(g)</b>	<b>Other Expenses</b>			
1	Other Expenses	558.37	2287.09	
	<b>Total other expenses</b>	<b>558.37</b>	<b>2287.09</b>	
	<b>Total expenses</b>	<b>2572.71</b>	<b>10009.49</b>	
<b>3</b>	<b>Total profit before exceptional items and tax</b>			
		<b>499.03</b>	<b>2432.59</b>	
<b>4</b>	Exceptional items	0	0	
<b>5</b>	<b>Total profit before tax</b>			
		<b>499.03</b>	<b>2432.59</b>	
<b>6</b>	<b>Tax expense</b>			
7	Current tax	115.58	521.44	
8	Deferred tax	7.54	28.43	
<b>9</b>	<b>Total tax expenses</b>			
		<b>123.12</b>	<b>549.87</b>	
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0	
<b>11</b>	<b>Net Profit Loss for the period from continuing operations</b>			
		<b>375.91</b>	<b>1882.72</b>	
12	Profit (loss) from discontinued operations before tax	0	0	
13	Tax expense of discontinued operations	0	0	
<b>14</b>	<b>Net profit (loss) from discontinued operation after tax</b>			
		<b>0</b>	<b>0</b>	
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0	
<b>16</b>	<b>Total profit (loss) for period</b>			
		<b>375.91</b>	<b>1882.72</b>	
17	Other comprehensive income net of taxes	-5.13	-3.01	
<b>18</b>	<b>Total Comprehensive Income for the period</b>			
		<b>370.78</b>	<b>1879.71</b>	
<b>19</b>	<b>Total profit or loss, attributable to</b>			
	Profit or loss, attributable to owners of parent			
	Total profit or loss, attributable to non-controlling interests			
<b>20</b>	<b>Total Comprehensive income for the period attributable to</b>			
	Comprehensive income for the period attributable to owners of parent			
	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
<b>21</b>	<b>Details of equity share capital</b>			
	Paid-up equity share capital	453.16	453.16	
	Face value of equity share capital	1	1	
22	Reserves excluding revaluation reserve	0		
<b>23</b>	<b>Earnings per share</b>			
<b>i</b>	<b>Earnings per equity share for continuing operations</b>			
	Basic earnings (loss) per share from continuing operations	0.83	4.15	
	Diluted earnings (loss) per share from continuing operations	0.83	4.15	
<b>ii</b>	<b>Earnings per equity share for discontinued operations</b>			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
<b>iii</b>	<b>Earnings per equity share (for continuing and discontinued operations)</b>			
	Basic earnings (loss) per share from continuing and discontinued operations	0.83	4.15	
	Diluted earnings (loss) per share from continuing and discontinued operations	0.83	4.15	
24	Debt equity ratio			Textual Information(1)
25	Debt service coverage ratio			Textual Information(2)
26	Interest service coverage ratio			Textual Information(

			3)
27	Disclosure of notes on financial results	Textual Information(4)	

**Text Block**

Textual Information(4)	<p>Current tax for the year include Current tax for earlier period Rs. 7.16</p> <p>The audited standalone financial results for the year ended 31 March 2025 has been prepared on the basis of the standalone annual financial statements in accordance with the Indian Accounting Standards (Ind AS) as notified under the Companies (Indian Accounting Standards) Rules 2015 (as amended) specified under section 133 of the Companies Act, 2013 and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation'), as amended were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meeting held on May 19, 2025. The Statutory Auditors of the Company have expressed an unmodified opinion on the audited standalone financial results for the year ended 31 March 2025.</p> <p>The figures for the quarter ended 31 March 2025 and 31 March 2024 are the balancing figures between the audited figures in respect of full financial year and the unaudited published year-to-date figures upto 31 December for respective years which were subject to limited review.</p> <p>The Company operates in one reportable business segment namely 'Pharmaceuticals' as per Ind AS 108 on 'Operating Segments'.</p> <p>The Board of Directors in the meeting held on 19 May 2025 have recommended final dividend of 0.80 per equity share of 1 each 80 for the Financial Year 2024-25.</p> <p>The above unaudited standalone financials results are available on the Company's website (<a href="http://www.marksanspharma.com">www.marksanspharma.com</a>) and stock exchanges websites, BSE (<a href="http://www.bseindia.com">www.bseindia.com</a>) and NSE (<a href="http://www.nseindia.com">www.nseindia.com</a>), where the shares of the Company are listed.</p>
------------------------	---

<b>Statement of Asset and Liabilities</b>	
Particulars	Year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2024
Date of end of reporting period	31-03-2025
Whether results are audited or unaudited	Audited
Nature of report standalone or consolidated	Standalone
<b>Assets</b>	
<b>1 Non-current assets</b>	
Property, plant and equipment	3535.94
Capital work-in-progress	
Investment property	
Goodwill	0
Other intangible assets	297.77
Intangible assets under development	
Biological assets other than bearer plants	
Investments accounted for using equity method	
<b>Non-current financial assets</b>	
Non-current investments	2657.53
Trade receivables, non-current	
Loans, non-current	0
Other non-current financial assets	10.84
<b>Total non-current financial assets</b>	<b>2668.37</b>
Deferred tax assets (net)	11.11
Other non-current assets	217.6
<b>Total non-current assets</b>	<b>6730.79</b>
<b>2 Current assets</b>	
Inventories	2052.1
<b>Current financial asset</b>	
Current investments	7.42
Trade receivables, current	5495.81
Cash and cash equivalents	602.68
Bank balance other than cash and cash equivalents	2084.23
Loans, current	0
Other current financial assets	22.91
<b>Total current financial assets</b>	<b>8213.05</b>
Current tax assets (net)	
Other current assets	557.08
Total current assets	10822.23
3 Non-current assets classified as held for sale	
4 Regulatory deferral account debit balances and related deferred tax Assets	
Total assets	17553.02
<b>Total current assets</b>	<b>10822.23</b>
3 Non-current assets classified as held for sale	
4 Regulatory deferral account debit balances and related deferred tax Assets	
<b>Total assets</b>	<b>17553.02</b>
<b>Equity and liabilities</b>	
<b>1 Equity</b>	
<b>Equity attributable to owners of parent</b>	
Equity share capital	453.16
Other equity	13381.7
<b>Total equity attributable to owners of parent</b>	<b>13834.86</b>
Non controlling interest	
<b>Total equity</b>	<b>13834.86</b>
<b>2 Liabilities</b>	
<b>Non-current liabilities</b>	
<b>Non-current financial liabilities</b>	
Borrowings, non-current	0
<b>Trade Payables, non-current</b>	
(A) Total outstanding dues of micro enterprises and small enterprises	
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	
<b>Total Trade payable</b>	
Other non-current financial liabilities	82.58
<b>Total non-current financial liabilities</b>	<b>82.58</b>
Provisions, non-current	57.7
Deferred tax liabilities (net)	121.53
Deferred government grants, Non-current	
Other non-current liabilities	
<b>Total non-current liabilities</b>	<b>261.81</b>
<b>Current liabilities</b>	
<b>Current financial liabilities</b>	
Borrowings, current	0
<b>Trade Payables, current</b>	
(A) Total outstanding dues of micro enterprises and small enterprises	36.33
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	1999.01
<b>Total Trade payable</b>	<b>2035.34</b>

	Other current financial liabilities	217.83
	<b>Total current financial liabilities</b>	2253.17
	Other current liabilities	1083.45
	Provisions, current	14.47
	Current tax liabilities (Net)	105.26
	Deferred government grants, Current	0
	<b>Total current liabilities</b>	3456.35
3	Liabilities directly associated with assets in disposal group classified as held for sale	0
4	Regulatory deferral account credit balances and related deferred tax liability	0
	<b>Total liabilities</b>	3718.16
	<b>Total equity and liabilities</b>	17553.02
	<b>Disclosure of notes on assets and liabilities</b>	<b>Textual Information(1)</b>

**Text Block**

Textual Information(1)

Other Current Financial Liabilities include Lease Liability - 25.84  
Other Intangible asset include Right of use asset Rs. 273.03

Other Comprehensive Income			
	Date of start of reporting period	01-01-2025	01-04-2024
	Date of end of reporting period	31-03-2025	31-03-2025
	Whether results are audited or unaudited	Audited	Audited
	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
1	Remeasurements of the net defined benefit liabilities/assets	-6.86	-4.02
	Total Amount of items that will not be reclassified to profit and loss	-6.86	-4.02
2	Income tax relating to items that will not be reclassified to profit or loss	-1.73	-1.01
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss		
5	Total Other comprehensive income	-5.13	-3.01

Cash flow statement, indirect		
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2024
Date of end of reporting period		31-03-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	2432.59
2	<b>Adjustments for reconcile profit (loss)</b>	
	Adjustments for finance costs	11.74
	Adjustments for decrease (increase) in inventories	-143.61
	Adjustments for decrease (increase) in trade receivables, current	-1826.86
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	-143.52
	Adjustments for decrease (increase) in other non-current assets	-0.71
	Adjustments for other financial assets, non-current	-6.51
	Adjustments for other financial assets, current	1.02
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	440.87
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	67.17
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	294.52
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	-9.1
	Adjustments for provisions, non-current	13.04
	Adjustments for other financial liabilities, current	27.07
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	-48.77
	Adjustments for dividend income	263.69
	Adjustments for interest income	182.16
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	40.06
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	-6.61
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	79.04
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	<b>Total adjustments for reconcile profit (loss)</b>	<b>-1657.01</b>
	<b>Net cash flows from (used in) operations</b>	<b>775.58</b>
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	465.4
	Other inflows (outflows) of cash	0
	<b>Net cash flows from (used in) operating activities</b>	<b>310.18</b>
3	<b>Cash flows from used in investing activities</b>	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	1.01
	Purchase of property, plant and equipment	1199.1
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0

	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	263.69
	Interest received	218.16
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	888.64
	<b>Net cash flows from (used in) investing activities</b>	<b>172.4</b>
<b>4</b>	<b>Cash flows from used in financing activities</b>	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	0
	Repayments of borrowings	0
	Payments of lease liabilities	27.29
	Dividends paid	271.9
	Interest paid	0
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	<b>Net cash flows from (used in) financing activities</b>	<b>-299.19</b>
	<b>Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes</b>	<b>183.39</b>
<b>5</b>	<b>Effect of exchange rate changes on cash and cash equivalents</b>	
	Effect of exchange rate changes on cash and cash equivalents	0
	<b>Net increase (decrease) in cash and cash equivalents</b>	<b>183.39</b>
	Cash and cash equivalents cash flow statement at beginning of period	419.29
	<b>Cash and cash equivalents cash flow statement at end of period</b>	<b>602.68</b>



28	Marksans Pharma Limited	AAACT3153G	Pharmaceuticals Australasia Pty Ltd	ZZZZZ9999Z	Subsidiary	Any other transaction	RECEIVABLE		0				
Total value of transaction during the reporting period													1

<b>Details of Impact of Audit Qualification</b>			
Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	M S K A & Associates	Yes	31-07-2027

